Literature DB >> 7875479

Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma.

E Adachi1, T Maeda, T Matsumata, K Shirabe, N Kinukawa, K Sugimachi, M Tsuneyoshi.   

Abstract

BACKGROUND/AIMS: Postoperative intrahepatic recurrence of human hepatocellular carcinoma is high. Recently, the relationship between proliferating cell activity in the cirrhotic liver and occurrence or recurrence of hepatocellular carcinoma has been reported.
METHODS: One hundred two resected cases of small hepatocellular carcinoma of < 3 cm in diameter without venous invasion or intrahepatic metastasis were examined to ascertain the factors affecting postoperative intrahepatic recurrence.
RESULTS: Cumulative intrahepatic recurrence rates at 1, 3, and 5 years after surgery were 12.0%, 57.2%, and 67.6%, respectively. The log-rank test indicated that serum albumin levels of < 3.7 g/dL, alanine aminotransferase levels of more than 54 IU/L, active inflammation in the nontumorous portion, and high proliferating cell nuclear antigen labeling index in the nontumorous portion (> 23.2%) were significant risk factors for recurrence. Tumor factors, including tumor size, histological grade, or alpha-fetoprotein level, were not significant risk factors. Cox's proportional hazard model identified that serum albumin level and alanine aminotransferase level were independently associated with intrahepatic recurrence after hepatectomy.
CONCLUSIONS: This study suggests that the principal cause linked to either a recurrence or a second new growth of hepatocellular carcinoma in the remnant liver after hepatectomy was the state of the underlying liver parenchyma as well as other tumor factors per se.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7875479     DOI: 10.1016/0016-5085(95)90450-6

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  69 in total

1.  A special recurrent pattern in small hepatocellular carcinoma after treatment: bile duct tumor thrombus formation.

Authors:  Qing-Yu Liu; Dong-Ming Lai; Chao Liu; Lei Zhang; Wei-Dong Zhang; Hai-Gang Li; Ming Gao
Journal:  World J Gastroenterol       Date:  2011-11-21       Impact factor: 5.742

Review 2.  Treatment strategies for hepatocellular carcinoma in cirrhosis.

Authors:  W Scott Helton; Adrian Di Bisceglie; Ravi Chari; Myron Schwartz; Jordi Bruix
Journal:  J Gastrointest Surg       Date:  2003 Mar-Apr       Impact factor: 3.452

3.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 4.  Management of hepatocellular carcinoma.

Authors:  P Fitzmorris; M Shoreibah; B S Anand; A K Singal
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-27       Impact factor: 4.553

5.  Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety.

Authors:  Y Nakamoto; E Mizukoshi; H Tsuji; Y Sakai; M Kitahara; K Arai; T Yamashita; K Yokoyama; N Mukaida; K Matsushima; O Matsui; S Kaneko
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

6.  Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma.

Authors:  Hung-Hsu Hung; Chien-Wei Su; Chiung-Ru Lai; Gar-Yang Chau; Che-Chang Chan; Yi-Hsiang Huang; Teh-Ia Huo; Pui-Ching Lee; Wei-Yu Kao; Shou-Dong Lee; Jaw-Ching Wu
Journal:  Hepatol Int       Date:  2010-09-24       Impact factor: 6.047

7.  Therapeutic results of computed-tomography-guided transcatheter arterial chemoembolization for local recurrence of hepatocellular carcinoma after initial transcatheter arterial chemoembolization: the results of 85 recurrent tumors in 35 patients.

Authors:  Mikio Tezuka; Keiji Hayashi; Yoichi Okada; Tetsuya Irie; Hiroyasu Ina
Journal:  Dig Dis Sci       Date:  2008-07-23       Impact factor: 3.199

8.  Accelerated carcinogenesis following liver resection in chronically inflamed livers: A window of opportunity for treatment.

Authors:  Amir Sonnenblick; Tamar Zahavi
Journal:  Biomed Rep       Date:  2017-03-30

9.  Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization.

Authors:  Takuma Arai; Akira Kobayashi; Ayumi Ohya; Masaaki Takahashi; Takahide Yokoyama; Akira Shimizu; Hiroaki Motoyama; Norihiko Furusawa; Tsuyoshi Notake; Noriyuki Kitagawa; Hiroshi Sakai; Hiroshi Imamura; Masumi Kadoya; Shin-Ichi Miyagawa
Journal:  Int J Clin Oncol       Date:  2013-11-12       Impact factor: 3.402

10.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.